In the crossover group of patients, six months of high-dose PPI therapy provided measurable symptomatic improvement (Table 3), while TF further improved control of a range of GERD symptoms, particularly regurgitation and atypical symptoms. The gene discussed is TF; the disease is gastroesophageal reflux disease.